Source: PR Newswire

Press Release: Janssen Research & Development : New Phase 2 Proof-of-Concept Study Shows Canagliflozin Combination Therapy May Support Chronic Weight Management

RARITAN, N.J., June 11, 2016 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) will announce findings of a multicenter, randomized, Phase 2 proof-of-concept clinical trial showing the combination therapy of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2)...

Read full article »
Est. Annual Revenue
$5.0-25M
Agree?
Est. Employees
25-100
Agree?